Multi-arm Optimization of Stroke Thrombolysis (MOST)
Diseases of the Nervous System
What is the purpose of this trial?
The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with 0.9mg/kg IV rt-PA within three hours of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care. Time of onset is defined as the last time the patient was last known to be well.
- Ages18 years and older
- Trial withUniversity of Cincinnati
- Start Date06/16/2020
- End Date02/28/2023
- Last Updated07/15/2021
- Study HIC#2000024503